{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:51:21Z","timestamp":1790034681489,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["HHSN-271-2018-00023-C"],"award-info":[{"award-number":["HHSN-271-2018-00023-C"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021250","name":"US Food and Drug Administration Human Foods Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cbi.2025.111669","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T07:00:31Z","timestamp":1752822031000},"page":"111669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety pharmacology of sibutramine analogues evaluated by in silico and in vitro biological target screening"],"prefix":"10.1016","volume":"420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-5859","authenticated-orcid":false,"given":"Michael F.","family":"Santillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Sprando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111669_bib1","first-page":"720","article-title":"Demystifying serotonin syndrome (or serotonin toxicity)","volume":"64","author":"Foong","year":"2018","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.cbi.2025.111669_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1467-789x.2000.00020.x","article-title":"An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action","volume":"1","author":"Nisoli","year":"2000","journal-title":"Obes. Rev."},{"key":"10.1016\/j.cbi.2025.111669_bib3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0960327111431704","article-title":"Serotonin syndrome following overdose of a non-prescription slimming product containing sibutramine: a case report","volume":"31","author":"Lam","year":"2012","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.cbi.2025.111669_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/WNF.0000000000000141","article-title":"A rare case of psychomotor disturbances linked to the use of an adulterated dietary supplement containing sibutramine","volume":"39","author":"Shapira","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.cbi.2025.111669_bib5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/15563650903018603","article-title":"Serotonin syndrome following sibutramine poisoning in a child, with sequential quantification of sibutramine and its primary and secondary amine metabolites in plasma","volume":"47","author":"Bucaretchi","year":"2009","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.cbi.2025.111669_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00414-023-03147-2","article-title":"Cardiogenic shock in a 28-year-old woman associated with sibutramine use","volume":"138","author":"Wan","year":"2024","journal-title":"Int. J. Leg. Med."},{"key":"10.1016\/j.cbi.2025.111669_bib7","article-title":"Sibutramine as a cause of sudden cardiac death","volume":"2021","author":"Rodriguez-Guerra","year":"2021","journal-title":"Case Rep. Cardiol."},{"key":"10.1016\/j.cbi.2025.111669_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/toxsci\/kfv180","article-title":"Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment","volume":"148","author":"Clements","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.cbi.2025.111669_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and Obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2025.111669_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4062\/biomolther.2015.033","article-title":"Cardiovascular safety pharmacology of sibutramine","volume":"23","author":"Yun","year":"2015","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.cbi.2025.111669_bib11","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/eurheartj\/ehm217","article-title":"Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial","volume":"28","author":"Torp-Pedersen","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cbi.2025.111669_bib12","series-title":"75 Fed. Reg. 80061, Abbott Laboratories, Inc.; Withdrawal of Approval of a New Drug Application for MERIDIA","year":"2010"},{"key":"10.1016\/j.cbi.2025.111669_bib13","article-title":"Summary of european union decisions on marketing authorisations in respect of medicinal products from 1 July 2010 to 31 August 2010 (decisions taken pursuant to article 34 of directive 2001\/83\/EC or article 38 of directive 2001\/82\/EC), off","year":"2010","journal-title":"J. Eur. Communities"},{"key":"10.1016\/j.cbi.2025.111669_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12916-016-0735-y","article-title":"Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.cbi.2025.111669_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.611361","article-title":"A systematic review of the european rapid alert system for food and feed: tendencies in illegal food supplements for weight loss","volume":"11","author":"Koncz","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111669_bib16","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.3390\/molecules26226903","article-title":"Adulteration of weight loss supplements by the illegal addition of synthetic pharmaceuticals","volume":"26","author":"Jairoun","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.cbi.2025.111669_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3337","article-title":"Unapproved pharmaceutical ingredients included in dietary supplements associated with US food and drug administration warnings","volume":"1","author":"Tucker","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cbi.2025.111669_bib18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/jcph.2046","article-title":"Continued risk of dietary supplements adulterated with approved and unapproved drugs: assessment of the US food and drug administration's tainted supplements database 2007 through 2021","volume":"62","author":"White","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111669_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s44211-022-00217-0","article-title":"Simultaneous detection of sibutramine and phenolphthalein in a diet jelly health food product that caused health problems","volume":"39","author":"Fukiwake","year":"2023","journal-title":"Anal. Sci."},{"key":"10.1016\/j.cbi.2025.111669_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfca.2022.104462","article-title":"The presence of unauthorized ingredients in dietary supplements: an analysis of the risk warning data in Korea","volume":"108","author":"Shin","year":"2022","journal-title":"J. Food Compos. Anal."},{"key":"10.1016\/j.cbi.2025.111669_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jpba.2013.10.038","article-title":"Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments","volume":"89","author":"Venhuis","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cbi.2025.111669_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/dta.1846","article-title":"Analysis of 40 weight loss compounds adulterated in health supplements by liquid chromatography quadrupole linear ion trap mass spectrometry","volume":"8","author":"Zeng","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.cbi.2025.111669_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jpba.2013.02.031","article-title":"Rapid screening and structural elucidation of a novel sibutramine analogue in a weight loss supplement: 11-desisobutyl-11-Benzylsibutramine","volume":"83","author":"Mans","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cbi.2025.111669_bib24","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/jssc.202101030","article-title":"Application of liquid chromatography-high resolution mass spectrometry and liquid chromatography-tandem mass spectrometry methods to 45 weight loss compounds in health functional food, food, and illegal drug","volume":"45","author":"Lee","year":"2022","journal-title":"J. Separ. Sci."},{"key":"10.1016\/j.cbi.2025.111669_bib25","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/19440049.2013.793826","article-title":"Isolation and identification of a sibutramine analogue adulterated in slimming dietary supplements","volume":"30","author":"Kim","year":"2013","journal-title":"Food Addit. Contam."},{"key":"10.1016\/j.cbi.2025.111669_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/rcm.2876","article-title":"Detection of sibutramine, its two metabolites and one analogue in a herbal product for weight loss by liquid chromatography triple quadrupole mass spectrometry and time-of-flight mass spectrometry","volume":"21","author":"Zou","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.cbi.2025.111669_bib27","first-page":"299","article-title":"Determination of 58 illegally added chemical drugs in functional leisure food by automatic QuEChERS-UPLC-MS\/MS","volume":"12","author":"Huang","year":"2022","journal-title":"Food Sci. Technol."},{"key":"10.1016\/j.cbi.2025.111669_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpba.2013.08.031","article-title":"Screening for multiple weight loss and related drugs in dietary supplement materials by flow injection tandem mass spectrometry and their confirmation by liquid chromatography tandem mass spectrometry","volume":"88","author":"Song","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cbi.2025.111669_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.forsciint.2018.03.021","article-title":"Isolation and structural characterization of a novel sibutramine analogue, chlorosipentramine, in a slimming dietary supplement, by using HPLC-PDA, LC\u2013Q-TOF\/MS, FT-IR, and NMR","volume":"286","author":"Yun","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.cbi.2025.111669_bib30","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1358\/dof.1988.013.08.63036","article-title":"Sibutramine hydrochloride","volume":"13","author":"Buckett","year":"1988","journal-title":"Drugs Future"},{"key":"10.1016\/j.cbi.2025.111669_bib31","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1039\/p19960002583","article-title":"Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites","volume":"1","author":"Jeffery","year":"1996","journal-title":"J. Chem. Soc., Perkin Trans."},{"key":"10.1016\/j.cbi.2025.111669_bib32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/op980093t","article-title":"A study and identification of potential By-Products of sibutramine","volume":"3","author":"Reddy","year":"1999","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.cbi.2025.111669_bib33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0731-7085(99)00303-9","article-title":"LC method for the determination of assay and purity of sibutramine hydrochloride and its enantiomers by chiral chromatography","volume":"22","author":"Radhakrishna","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cbi.2025.111669_bib34","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1016\/j.tetasy.2003.08.042","article-title":"New resolution approach for large-scale preparation of enantiopure didesmethylsibutramine (DDMS)","volume":"14","author":"Han","year":"2003","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.cbi.2025.111669_bib35","unstructured":"U.S. Pharmacopial Convention, Sibutramine Hydrochloride Monograph, USP41-NF36, pp. DocID: GUID-90BE90EBD-E99A92-94A69-88AB-99DC80474F80937_80471_en-USNO."},{"key":"10.1016\/j.cbi.2025.111669_bib36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic drug\u2013drug interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2025.111669_bib37","doi-asserted-by":"crossref","first-page":"14360","DOI":"10.1021\/acsomega.9b02221","article-title":"Evolving concept of activity cliffs","volume":"4","author":"Stumpfe","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.cbi.2025.111669_bib38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cbi.2025.111669_bib39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nrd3845-c1","article-title":"Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective","volume":"14","author":"Papoian","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cbi.2025.111669_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106869","article-title":"A practical guide to secondary pharmacology in drug discovery","volume":"105","author":"Jenkinson","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.cbi.2025.111669_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41573-024-00942-3","article-title":"The state of the art in secondary pharmacology and its impact on the safety of new medicines","volume":"23","author":"Brennan","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cbi.2025.111669_bib42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.5195\/jmla.2018.515","article-title":"SciFinder","volume":"106","author":"Gabrielson","year":"2018","journal-title":"J. Med. Libr. Assoc."},{"key":"10.1016\/j.cbi.2025.111669_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13321-015-0068-4","article-title":"InChI, the IUPAC international chemical identifier","volume":"7","author":"Heller","year":"2015","journal-title":"J. Cheminf."},{"key":"10.1016\/j.cbi.2025.111669_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/ci00057a005","article-title":"SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules","volume":"28","author":"Weininger","year":"1988","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.cbi.2025.111669_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122502","article-title":"Metabolic analysis of the illegal analogues of anti-obesity drugs using LC-Q-TOF-MS\/MS","volume":"1163","author":"Jeong","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.cbi.2025.111669_bib46","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.108.020727","article-title":"Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes","volume":"36","author":"Bae","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2025.111669_bib47","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.jchromb.2009.07.013","article-title":"Analysis of sibutramine metabolites as N-trifluoroacetamide and O-trimethylsilyl derivatives by gas chromatography\u2013mass spectrometry in urine","volume":"877","author":"Sardela","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.cbi.2025.111669_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/rcm.2807","article-title":"Detection of sibutramine administration: a gas chromatography\/mass spectrometry study of the main urinary metabolites","volume":"21","author":"Strano-Rossi","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.cbi.2025.111669_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J. Cheminf."},{"key":"10.1016\/j.cbi.2025.111669_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fdata.2019.00025","article-title":"Novel computational approach to predict off-target interactions for small molecules","volume":"2","author":"Rao","year":"2019","journal-title":"Frontiers in Big Data"},{"key":"10.1016\/j.cbi.2025.111669_bib51","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/jat.4478","article-title":"Predicting binding between 55 cannabinoids and 4,799 biological targets by in silico methods","volume":"43","author":"Santillo","year":"2023","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.cbi.2025.111669_bib52","series-title":"Chemogenomics: Methods and Applications","first-page":"159","article-title":"Database systems for knowledge-based discovery","author":"Jagarlapudi","year":"2009"},{"key":"10.1016\/j.cbi.2025.111669_bib53","doi-asserted-by":"crossref","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","article-title":"BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology","volume":"44","author":"Gilson","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cbi.2025.111669_bib54","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cbi.2025.111669_bib55","series-title":"NIMH PDSP Assay Protocol Book, Version III","author":"Roth","year":"2018"},{"key":"10.1016\/j.cbi.2025.111669_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2025.111669_bib57","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111669_bib58","series-title":"Advances in Computational Toxicology: Methodologies and Applications in Regulatory Science","first-page":"141","article-title":"An overview of national toxicology program's toxicogenomic applications: drugmatrix and ToxFX","author":"Svoboda","year":"2019"},{"key":"10.1016\/j.cbi.2025.111669_bib59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.cbi.2025.111669_bib60","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1021\/jm300131x","article-title":"The experimental uncertainty of heterogeneous public Ki data","volume":"55","author":"Kramer","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111669_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061007","article-title":"Comparability of mixed IC50 data \u2013 a statistical analysis","volume":"8","author":"Kalliokoski","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2025.111669_bib62","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/pr.111.005439","article-title":"Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy","volume":"65","author":"Obach","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.cbi.2025.111669_bib63","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00044-023-03089-9","article-title":"A MIST conception: what has been learned from twenty years of human metabolite safety assessment?","volume":"32","author":"Luffer-Atlas","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.cbi.2025.111669_bib64","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/dmd.117.079848","article-title":"A decade in the MIST: learnings from investigations of drug metabolites in drug development under the \u201cMetabolites in Safety Testing\u201d regulatory guidance","volume":"46","author":"Schadt","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2025.111669_bib65","series-title":"Synthesis, Methods of Using, and Compositions of Hydroxylated Cyclobutylalkylamines, Patent WO2002046138A2","author":"Senanayake","year":"2002"},{"key":"10.1016\/j.cbi.2025.111669_bib66","series-title":"Methods of Preparing and Using 2-hydroxy Derivatives of Sibutramine and Its Metabolites, Patent WO2003022259A1","author":"Senanayake","year":"2003"},{"key":"10.1016\/j.cbi.2025.111669_bib68","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1038\/s41467-023-40064-9","article-title":"A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs","volume":"14","author":"Sutherland","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cbi.2025.111669_bib69","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0b013e31817fde95","article-title":"Appetite suppressants, cardiac valve disease and combination pharmacotherapy","volume":"16","author":"Rothman","year":"2009","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.cbi.2025.111669_bib70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.cbi.2025.111669_bib71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","article-title":"Pharmacological profile of antidepressants and related compounds at human monoamine transporters","volume":"340","author":"Tatsumi","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111669_bib72","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00204-012-0815-5","article-title":"Toxicity of amphetamines: an update","volume":"86","author":"Carvalho","year":"2012","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.cbi.2025.111669_bib73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","article-title":"Mechanisms of neurotransmitter release by amphetamines: a review","volume":"75","author":"Sulzer","year":"2005","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.cbi.2025.111669_bib74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00023210-200317080-00001","article-title":"Mechanism of action of St john's wort in depression","volume":"17","author":"Butterweck","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.cbi.2025.111669_bib75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2009.02.012","article-title":"Ginkgo biloba extract (EGb761\u00ae) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment","volume":"60","author":"Fehske","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cbi.2025.111669_bib76","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1124\/jpet.120.000129","article-title":"Amphetamine-like neurochemical and cardiovascular effects of \u03b1-Ethylphenethylamine analogs found in dietary supplements","volume":"376","author":"Schindler","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2025.111669_bib77","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.118.255976","article-title":"The supplement adulterant \u03b2-Methylphenethylamine increases blood pressure by acting at peripheral norepinephrine transporters","volume":"369","author":"Schindler","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2025.111669_bib78","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.103.053975","article-title":"In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates","volume":"307","author":"Rothman","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2025.111669_bib79","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/ph3082398","article-title":"Combinations of drugs in the treatment of obesity","volume":"3","author":"Halpern","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cbi.2025.111669_bib80","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DMSO.S95299","article-title":"Off-label drugs for weight management, diabetes","volume":"10","author":"Hendricks","year":"2017","journal-title":"Metab. Syndr. Obes."},{"key":"10.1016\/j.cbi.2025.111669_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.722889","article-title":"An overview of cell-based assay platforms for the solute carrier family of transporters","volume":"12","author":"Dvorak","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111669_bib82","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1021\/acs.est.7b00650","article-title":"An intuitive approach for predicting potential human health risk with the Tox21 10k library","volume":"51","author":"Sipes","year":"2017","journal-title":"Environ. Sci. Technol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725002996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725002996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:22:36Z","timestamp":1757118156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279725002996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":81,"alternative-id":["S0009279725002996"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111669","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety pharmacology of sibutramine analogues evaluated by in silico and in vitro biological target screening","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111669"}}